J Med Microbiol NEW Faster Access
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Palmisano, L.
Right arrow Articles by Vella, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Palmisano, L.
Right arrow Articles by Vella, S.
Agricola
Right arrow Articles by Palmisano, L.
Right arrow Articles by Vella, S.
J Med Microbiol 58 (2009), 121-124; DOI: 10.1099/jmm.0.004630-0
© 2009 Society for General Microbiology
ISSN 0022-2615

Modifications of residual viraemia in human immunodeficiency virus-1-infected subjects undergoing repeated highly active antiretroviral therapy interruptions

Lucia Palmisano, Marina Giuliano, Raffaella Bucciardini, Mauro Andreotti, Vincenzo Fragola, Maria F. Pirillo, Liliana E. Weimer, Maria G. Mancini and Stefano Vella

Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Rome, Italy

Correspondence
Lucia Palmisano
lucia.palmisano{at}iss.it

Received July 2, 2008
Accepted September 30, 2008

Residual viraemia is detectable in the majority of human immunodeficiency virus (HIV)-infected subjects with plasma HIV-1 RNA <50 copies ml–1. In the present study, the impact of repeated treatment interruptions on residual HIV-1 viraemia was investigated in 58 subjects enrolled in the ISS-PART, a multicentre, randomized clinical trial comparing 24 months of continuous (arm A) and intermittent (arm B) highly active antiretroviral therapy (HAART). Residual viraemia was measured by a modified Roche Amplicor HIV-1 RNA assay (limit of detection 2.5 copies ml–1). At baseline, the median value of residual viraemia was 2.5 copies ml–1 in both arms; after 24 months, the median value was 2.5 in arm A and 8.3 in arm B. The median change from baseline to month 24 was significantly different between patients under continuous or intermittent HAART: 0 copies ml–1 (range –125.2 to +82.7) of HIV-1 RNA in arm A versus 2.1 copies ml–1 (range –80 to +46.8) in arm B (P=0.024). These results suggest that intermittent HAART tends to modify HIV-1 viraemia set point even if a virological response is achieved after HAART reinstitution.

Abbreviations: HAART, highly active antiretroviral therapy; STIs, Structured Treatment Interruptions.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL J MED MICROBIOL MICROBIOLOGY J GEN VIROL ALL SGM JOURNALS
Copyright © 2009 Society for General Microbiology.